ArticleJournal of Alzheimer's disease : JAD2018
Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults.
Article in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Effects of simvastatin on white matter integrity in healthy middle-aged adults.Annals of clinical and translational neurology · 2021Trial
- SIRT1 in brain aging: molecular mechanisms and therapeutic potential of pharmacological and natural modulators.Biogerontology · 2026Review
- Leukoaraiosis: Epidemiology, Imaging, Risk Factors, and Management of Age-Related Cerebral White Matter Hyperintensities.Journal of stroke · 2024Review
- Association between hemoglobin trajectories and the incidence of dementia in a cohort of females aged 55-79 years.PloS one · 2024Article
- Statin use is associated with higher white matter hyperintensity volumes and lower grey matter volumes.Brain communications · 2024Article
- Does statin use affect amyloid beta deposition and brain metabolism?CNS neuroscience & therapeutics · 2023Article
- Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review.Brain sciences · 2022Review
- Cholesterol biosynthesis defines oligodendrocyte precursor heterogeneity between brain and spinal cord.Cell reports · 2022Article
- Statins and cognition: Modifying factors and possible underlying mechanisms.Frontiers in aging neuroscience · 2022Review
- Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.Alzheimer's research & therapy · 2021Article
- ESO Guideline on covert cerebral small vessel disease.European stroke journal · 2021Article
- Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- Cerebrovascular Disease and Statins.Frontiers in cardiovascular medicine · 2021Review
- Promoting Successful Cognitive Aging: A Ten-Year Update.Journal of Alzheimer's disease : JAD · 2021Review
- Regulation of Small GTPase Prenylation in the Nervous System.Molecular neurobiology · 2020Review
- Statin therapy: does sex matter?Menopause (New York, N.Y.) · 2019Review
- Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures.Neurology · 2019Article
- Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a Consequence of It?Journal of clinical medicine · 2019Review
- Statins and Inflammation: New Therapeutic Opportunities in Psychiatry.Frontiers in psychiatry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundStatins have been proposed to reduce the risk of Alzheimer's disease (AD).
objectiveAssess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia.
methodsMethods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging.
resultsStatin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (≤3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden.
conclusionsLong-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.